What we are doing is post-hoc and has been done with many AD trials, which have subsequently failed. So those trials were also "ahead of the curve" by that definition. Of course, they were no such thing. Nor are we.
We are simply trying to narrow down what the correlates, if any, to 2-73 efficacy might be based on our 2A data, to better design our next trial. This has been done many times before in other trials, let's hope we find something actual and not spurious (there's luck involved here, we are dealing with unknowables: correlation is not causation), and see what it gets us.